Meiotic Recombination: Birth and death of a protein
The ways in which recombination sites are determined during meiosis are becoming clearer following a phylogenomic analysis for 225 different species.
- CNRS-Université de Montpellier, France
Each of our cells carry two almost identical copies of each of our chromosomes, one copy inherited from each parent. These small differences, which are mainly caused by mutations, make an important contribution to the genetic diversity observed in humans and other species. During meiosis, the chromosomes from each parent pair up and then swap segments of DNA: this process, which is known as meiotic recombination, is important for diversity and is essential for fertility (Hunter, 2015). An important scientific goal is to understand where recombination occurs on chromosomes, what molecular processes are involved, and how meiotic recombination affects the evolution of the genome.
Many components of the molecular machinery involved in meiotic recombination are similar in fungi, plants and animals. However, some features of meiotic recombination have not been conserved across species. For example, in all yeast, plant and vertebrate species studied to date, meiotic recombination happens at specific regions within the chromosomes known as hotspots. In flies and worms, on the other hand, it happens at many more locations within the chromosomes. Moreover, there are two main pathways that direct meiotic recombination to hotspots.
The hotspots in yeast, plant and some vertebrate species are located at regions of the genome that are easier to access, such as regulatory regions, transcription start sites or CpG islands (regions with a high frequency of CG dinucleotides; de Massy, 2013). These hotspots are stable over evolutionary time (Lam and Keeney, 2015; Singhal et al., 2015) and this pathway is likely ancestral among eukaryotes.
In contrast, the hotspots in many mammals, including humans, apes and mice, are found at locations where a protein called PRDM9 can bind to the DNA (Figure 1). In particular, the binding sites (and, therefore, the location of the hotspots) are determined by the amino acid sequence of the zinc finger domain of PRDM9 and are characterized by histone modifications mediated by the PR/SET domain of PRDM9 (Baudat et al., 2010; Myers et al., 2010; Parvanov et al., 2010). However, over the course of time the binding sites have rapidly accumulated mutations that can disrupt the PRDM9 binding. This is correlated with the fast evolution of the zinc finger domain, which ensures that PRDM9 can maintain its binding activity in the genome.
Figure 1
The evolution of PRDM9 and meiotic recombination.
The full-length PRDM9 protein contains four domains: KRAB, SSXRD, PR/SET and ZnF (short for Zinc finger). PRDM9 plays an important role in meiotic recombination but, over the course of evolution, many species have either completely lost this protein (light grey line in the simplified phylogenetic tree to the left), or now carry truncated versions of it (dark grey lines). In species with full-length PRDM9 (top row), recombination hotspots are located at sites where PRDM9 binds to the DNA in the genome, and three residues in the PR/SET domain that are essential for the recombination process (Y276, Y341 and Y357; Wu et al., 2013) are conserved: moreover, the locations of the hotspots change over time due to the rapid evolution of the ZnF domain. In species with truncated PRDM9 (next four rows), recombination hotspots are located at transcription start sites (TSS) or at CpG islands, the three residues in the PR/SET domain are not conserved, and the ZnF domain (if present) does not evolve rapidly. In species that lack PRDM9 (bottom row), recombination hotspots are located at transcription start sites (TSS) or at CpG islands.
It is still only partly understood why such a molecular strategy has evolved and why the PRDM9 gene is present in some vertebrates but lost in others (Ponting, 2011). Now, in eLife, Molly Przeworski of Columbia University and colleagues – including Zachary Baker and Molly Schumer as joint first authors – report the results of a series of experiments that shed light on some of these questions (Baker et al., 2017).
By analyzing the DNA and RNA sequences of 225 different species, Baker et al. demonstrate that PRDM9 is not specific to mammals, and they show that even distantly related animals have genes that produce their own equivalents of the PRDM9 protein. They go on to show that while the zinc finger domain evolves rapidly in these species, the other three domains in PRDM9 (the KRAB, SSRXD and PR/SET domains) are conserved (Figure 1). This suggests that the role of PRDM9 appeared very early during the evolution of vertebrates and has been maintained in these different lineages.
Baker et al. – who are based at Columbia, Harvard, Texas A&M and the CICHAZ research station in Mexico – also discovered that several species had independently lost the ability to make PRDM9, while others produced only truncated versions of the protein. For example, the version of PRDM9 found in teleost fish does not contain a domain called the KRAB domain, which is found in full-length PRDM9: moreover, the zinc finger domain is not evolving rapidly in these fish, and three of the amino acids involved in the catalytic activity of PR/SET are not conserved (Figure 1). It appears that the truncated PRDM9 proteins have no influence on the location of recombination hotspots.
Baker et al. investigated this hypothesis by analyzing recombination sites in swordtail fish hybrids between two species of fish belonging to the genus Xiphophorus. In these hybrids, in which PRDM9 lacks both the KRAB and SSXRD domains, meiotic recombination occurs preferentially at CpG islands, similar to what has been reported for dogs and birds, which completely lack the gene for PRDM9 (Figure 1; Auton et al., 2013; Axelsson et al., 2012; Singhal et al., 2015). This suggests that the ancestral pathway of recombination (that is, a pathway that existed before the emergence of PRDM9) is active in swordtail fish. Moreover, since the gene for PRDM9 is still under selection in these fish, it must have other roles that remain to be determined. Thus, two important new conclusions emerge from the work of Baker, Schumer, Przeworski and colleagues. First, the full length PRDM9 is required for directing recombination, and second, a shorter version of the protein may still have a relevant role.
Overall, there is also a clear divide between the two hotspot localization pathways. However, several questions remain open, and more research is needed to discover why PRDM9 has evolved in the first place, and why it is maintained in some species but not in others. Answers to these puzzles may come from a better understanding of the underlying molecular properties and how the different pathways have affected the pattern of genetic diversity and selection.
References
-
Meiotic recombination: The essence of heredityCold Spring Harbor Perspectives in Biology 7:a016618.https://doi.org/10.1101/cshperspect.a016618
-
What are the genomic drivers of the rapid evolution of PRDM9?Trends in Genetics 27:165–171.https://doi.org/10.1016/j.tig.2011.02.001
Article and author information
Author details
Publication history
Copyright
© 2017, Clément et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,932
- views
-
- 240
- downloads
-
- 3
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Meiotic Recombination: Birth and death of a protein
eLife 6:e29502.
https://doi.org/10.7554/eLife.29502
Further reading
-
- Cell Biology
- Genetics and Genomics
A glaucoma polygenic risk score (PRS) can effectively identify disease risk, but some individuals with high PRS do not develop glaucoma. Factors contributing to this resilience remain unclear. Using 4,658 glaucoma cases and 113,040 controls in a cross-sectional study of the UK Biobank, we investigated whether plasma metabolites enhanced glaucoma prediction and if a metabolomic signature of resilience in high-genetic-risk individuals existed. Logistic regression models incorporating 168 NMR-based metabolites into PRS-based glaucoma assessments were developed, with multiple comparison corrections applied. While metabolites weakly predicted glaucoma (Area Under the Curve = 0.579), they offered marginal prediction improvement in PRS-only-based models (p=0.004). We identified a metabolomic signature associated with resilience in the top glaucoma PRS decile, with elevated glycolysis-related metabolites—lactate (p=8.8E-12), pyruvate (p=1.9E-10), and citrate (p=0.02)—linked to reduced glaucoma prevalence. These metabolites combined significantly modified the PRS-glaucoma relationship (Pinteraction = 0.011). Higher total resilience metabolite levels within the highest PRS quartile corresponded to lower glaucoma prevalence (Odds Ratiohighest vs. lowest total resilience metabolite quartile=0.71, 95% Confidence Interval = 0.64–0.80). As pyruvate is a foundational metabolite linking glycolysis to tricarboxylic acid cycle metabolism and ATP generation, we pursued experimental validation for this putative resilience biomarker in a human-relevant Mus musculus glaucoma model. Dietary pyruvate mitigated elevated intraocular pressure (p=0.002) and optic nerve damage (p<0.0003) in Lmx1bV265D mice. These findings highlight the protective role of pyruvate-related metabolism against glaucoma and suggest potential avenues for therapeutic intervention.
-
- Cancer Biology
- Genetics and Genomics
Tyrosine kinases play a crucial role in cell proliferation and survival and are extensively investigated as targets for cancer treatment. However, the efficacy of most tyrosine kinase inhibitors (TKIs) in cancer therapy is limited due to resistance. In this study, we identify a synergistic combination therapy involving TKIs for the treatment of triple negative breast cancer. By employing pairwise tyrosine kinase knockout CRISPR screens, we identify FYN and KDM4 as critical targets whose inhibition enhances the effectiveness of TKIs, such as NVP-ADW742 (IGF-1R inhibitor), gefitinib (EGFR inhibitor), and imatinib (ABL inhibitor) both in vitro and in vivo. Mechanistically, treatment with TKIs upregulates the transcription of KDM4, which in turn demethylates H3K9me3 at FYN enhancer for FYN transcription. This compensatory activation of FYN and KDM4 contributes to the resistance against TKIs. FYN expression is associated with therapy resistance and persistence by demonstrating its upregulation in various experimental models of drug-tolerant persisters and residual disease following targeted therapy, chemotherapy, and radiotherapy. Collectively, our study provides novel targets and mechanistic insights that can guide the development of effective combinatorial targeted therapies, thus maximizing the therapeutic benefits of TKIs.
